SAN DIEGO — You've been free of COVID-19 symptoms for two days. Then the coughing, fatigue and headaches return. Join the growing number of people experiencing what's being called COVID rebound.
And a new study by a team of University of California, San Diego researchers found that those who took the antiviral drug Paxlovid to alleviate their initial symptoms are more likely to see a recurrence.
A research letter that just appeared in the journal Infectious Diseases studied 158 San Diego County residents who received the drug early in their courses of illness. Of those, 108 saw their symptoms resolve for at least two consecutive days within a 28-day period after they became infected. But that illness-free period was short-lived for 48 people, meaning that 44% reported those telltale signs of coronavirus infection resurfacing.
